Instil Bio Reports Exit/Disposal Costs
Ticker: TIL · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1789769
| Field | Detail |
|---|---|
| Company | Instil Bio, INC. (TIL) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.000001, $5.5 m, $2.2 m, $2.0 m, $1.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, 8-K
TL;DR
Instil Bio is incurring costs for exiting or disposing of something, details TBD.
AI Summary
Instil Bio, Inc. filed an 8-K on September 6, 2024, reporting costs associated with exit or disposal activities as of September 1, 2024. The filing does not specify the exact dollar amount of these costs or the nature of the disposal activities.
Why It Matters
This filing indicates Instil Bio is undergoing restructuring or divesting assets, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing signals potential restructuring or asset sales, which carries inherent business and financial risks.
Key Players & Entities
- Instil Bio, Inc. (company) — Registrant
- September 1, 2024 (date) — Date of earliest event reported
- September 6, 2024 (date) — Filing date
- 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 (address) — Principal Executive Offices
FAQ
What specific activities are associated with the exit or disposal?
The filing does not specify the nature of the exit or disposal activities.
What is the total dollar amount of the costs associated with the exit or disposal?
The filing does not disclose the specific dollar amount of these costs.
When did these exit or disposal activities commence or become effective?
The costs are reported as of September 1, 2024.
What is the primary business of Instil Bio, Inc.?
Instil Bio, Inc. is in the business of Biological Products (No Diagnostic Substances).
What is the Commission File Number for Instil Bio, Inc.?
The Commission File Number for Instil Bio, Inc. is 001-40215.
Filing Stats: 758 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-09-06 17:02:29
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market L
- $5.5 m — aggregate restructuring costs of up to $5.5 million, including asset impairment charg
- $2.2 m — uding asset impairment charges of up to $2.2 million, employee termination costs, incl
- $2.0 m — g severance and other benefits of up to $2.0 million, and contract termination costs o
- $1.3 million — and contract termination costs of up to $1.3 million. The charges that the Company expects t
Filing Documents
- til-20240901.htm (8-K) — 31KB
- 0001628280-24-039726.txt ( ) — 155KB
- til-20240901.xsd (EX-101.SCH) — 2KB
- til-20240901_lab.xml (EX-101.LAB) — 22KB
- til-20240901_pre.xml (EX-101.PRE) — 13KB
- til-20240901_htm.xml (XML) — 3KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. On September 1, 2024, the Board of Directors of Instil Bio, Inc. (the "Company") approved a restructuring plan (the "Plan") to effect the closure of what remains of the Company's Manchester, UK operations, including eliminating its remaining UK workforce. The workforce reduction is expected to be substantially complete by the end of 2024. In connection with the Plan, the Company currently estimates that it will incur aggregate restructuring costs of up to $5.5 million, including asset impairment charges of up to $2.2 million, employee termination costs, including severance and other benefits of up to $2.0 million, and contract termination costs of up to $1.3 million. The charges that the Company expects to incur in connection with the Plan, which exclude tax charges, are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Plan. Cautionary Note Regarding Forward-Looking Statements This Current Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the scope and the timing of the restructuring and the expected costs related to the restructuring, which are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Forward-looking statements are based on management's current expectations and restructuring cost estimates and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including those discussed in the section titl
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Dated: September 6, 2024 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)